Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment.
Benjamin N SchmeusserArnold R PalaciosEric R MidenbergReza NabavizadehDattatraya H PatilRobert Donald HarveyJanetta BryksinMichael J ConnorKenneth OganMehmet A BilenViraj A MasterPublished in: Cancer (2023)
Black patients experience worse oncologic outcomes and are underrepresented in clinical trials. Kidney function, as estimated by glomerular filtration rate equations, is a factor in who can and cannot be in a clinical trial. Race is a variable in some of these equations. For Black patients, removing race from these equations leads to the calculation of lower kidney function. Lower estimated kidney function may result in more black patients being excluded from clinical trials. The inclusion of all races in clinical trials is important for offering best care to everyone and for making results from clinical trials applicable to everyone.
Keyphrases
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prostate cancer
- healthcare
- phase ii
- randomized controlled trial
- type diabetes
- squamous cell carcinoma
- open label
- health insurance
- chronic pain
- patient reported outcomes
- double blind
- papillary thyroid
- squamous cell
- glycemic control
- radical prostatectomy
- monte carlo